DOCSLIB.ORG

The Broad Institute, Inc. (The “Institution”) and the Bank of New York Mellon Trust Company, N.A., As Trustee (The “Trustee”)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Broad Institute, Inc. (The “Institution”) and the Bank of New York Mellon Trust Company, N.A., As Trustee (The “Trustee”) PRELIMINARY OFFICIAL STATEMENT DATED OCTOBER 26, 2017 NEW ISSUE – BOOK-ENTRY-ONLY RATING: See “DESCRIPTION OF RATINGS” herein. In the opinion of Hinckley, Allen & Snyder LLP, Bond Counsel, based upon an analysis of existing law and assuming, among other matters, compliance with certain covenants, interest on the Bonds is excluded from gross income for federal income tax purposes under the Internal Revenue Code of 1986, as amended (the “Code”). Interest on the Bonds is not a specific preference item for purposes of the federal individual or corporate alternative minimum taxes, although such interest is included in adjusted current earnings when calculating corporate alternative minimum taxable income. Under existing law, interest on the Bonds and any profit on the sale of the Bonds are exempt from Massachusetts personal income taxes and the Bonds are exempt from Massachusetts personal property taxes. Bond Counsel expresses no opinion regarding any other tax consequences related to the ownership or disposition of, or the accrual or receipt of interest on, the Bonds. See “TAX EXEMPTION” herein. $248,000,000* MASSACHUSETTS DEVELOPMENT FINANCE AGENCY Revenue Bonds The Broad Institute Issue, Series 2017 Dated: Date of Delivery Due: April 1, as shown on inside cover The Massachusetts Development Finance Agency (the “Issuer”) is issuing its Revenue Bonds, The Broad Institute Issue, Series 2017 (the “Bonds”). The Bonds will be issued only as fully-registered bonds without coupons and, when issued, will be registered in the name of Cede & Co., as Bondowner and nominee of The Depository Trust Company (“DTC”), New York, New York. DTC will act as securities depository for the Bonds. Purchases of the Bonds will be made in book- entry form, in the denomination of $5,000 or any multiple thereof. Purchasers will not receive certificates representing their interest in Bonds purchased. So long as Cede & Co. is the Bondowner, as nominee of DTC, references herein to the Bondowners or registered owners shall mean Cede & Co., as aforesaid, and shall not mean the Beneficial Owners of the Bonds. See “BOOK-ENTRY-ONLY SYSTEM” herein. The Bank of New York Mellon Trust Company, N.A. will act as trustee for the Bonds (the “Trustee”). Principal or redemption price of and interest on the Bonds will be payable as described herein. So long as DTC or its nominee, Cede & Co., is the Bondowner, such payments will be made directly to such Bondowner, as more fully described herein. The Bonds will bear interest at the rates and mature on the dates set forth on the inside cover hereof. Interest on the Bonds will be payable on April 1, 2018 and semi-annually thereafter on each October 1 and April 1 to the Bondowners of record as of the close of business on the 15th day of the month preceding such interest payment dates. The Bonds are subject to optional, mandatory and special redemption under certain circumstances prior to maturity as described herein. The Bonds shall be special obligations of the Issuer payable solely from the Revenues (as defined herein) of the Issuer, including payments to the Trustee for the account of the Issuer by The Broad Institute, Inc. (the “Institution”) in accordance with the provisions of a Loan and Trust Agreement, dated as of November 1, 2017 (the “Agreement”), among the Issuer, the Institution and the Trustee with respect to the Bonds. Such payments required to be paid by the Institution will be in amounts sufficient to pay, when due, principal or redemption price of and interest on the Bonds, all in accordance with the Agreement. The payments pursuant to the Agreement are a general obligation of the Institution. Reference is made to this Official Statement for pertinent security provisions of the Bonds. THE BONDS DO NOT CONSTITUTE A GENERAL OBLIGATION OF THE ISSUER OR A DEBT OR PLEDGE OF THE FAITH AND CREDIT OF THE COMMONWEALTH OF MASSACHUSETTS OR ANY POLITICAL SUBDIVISION THEREOF. THE PRINCIPAL OR REDEMPTION PRICE OF AND INTEREST ON THE BONDS ARE PAYABLE SOLELY FROM THE REVENUES AND FUNDS PLEDGED FOR THEIR PAYMENT UNDER THE AGREEMENT. THE ISSUER HAS NO TAXING POWER UNDER THE ACT. This cover page contains certain information for general reference only. It is not intended to be a summary of the terms of the Bonds. Investors are advised to read this entire Official Statement, including the appendices, to obtain information essential to making an informed investment decision. The Bonds will be offered when, as, and if issued and accepted by the Underwriters, subject to prior sale, to withdrawal or modification of the offer without notice and to approval of legality and certain other matters by Hinckley, Allen & Snyder LLP, Boston, Massachusetts, Bond Counsel to the Issuer. Certain legal matters will be passed upon for the Institution by its counsel, Ropes & Gray LLP, Boston, Massachusetts. Certain legal matters will be passed upon for the Underwriters by their counsel, Greenberg Traurig, LLP, Boston, Massachusetts. The Bonds are expected to be available for delivery to DTC in New York, New York or its custodial agent on or about November ___, 2017. Morgan Stanley BofA Merrill Lynch J.P. Morgan November __, 2017 * This Preliminary Official Statement and the information contained herein are subject to completion, amendment or other change without notice. The securities described herein may not be sold nor may offers to buy be accepted prior the to to offers sold nor may be not The securities described herein may This Preliminary change without notice. other subject to completion, amendment or contained herein are the information and Official Statement any sale of these securities any buy, nor shall there be in jurisdiction offer to Under no circumstances shall this Preliminaryoffer to sell or the solicitation of an Official Statement constitute an form. in final date the Official Statement is delivered such jurisdiction. prior of any or qualification under the securities to registration be unlawful laws solicitation or sale would in which such offer, Preliminary, subject to change. $248,000,000∗ Massachusetts Development Finance Agency Revenue Bonds The Broad Institute Issue, Series 2017 Maturities, Amounts, Rates, Prices/Yields and CUSIP† Numbers $____________ Serial Bonds Due Principal Interest Price/ CUSIP† April 1* Amount Rate Yield Number 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 $___________ _____% Term Bond due April 1, 2041* Price/Yield _____% CUSIP† Number: _________ ___________________ ∗ Preliminary, subject to change. † CUSIP® is a registered trademark of the American Bankers Association. CUSIP Global Services (“CGS”) is managed on behalf of the American Bankers Association by S&P Capital IQ. Copyright© 2017 CUSIP Global Services. All rights reserved. CUSIP® data herein is provided by CUSIP Global Services. This data is not intended to create a database and does not serve in any way as a substitute for the CGS database. The CUSIP® numbers listed above are being provided solely for the convenience of Bondowners only at the time of issuance of the Bonds, and no representation is made with respect to the correctness thereof. The CUSIP® number for a specific maturity is subject to being changed after the issuance of the Bonds as a result of various subsequent actions including, but not limited to, a refunding in whole or in part of such maturity. None of the Issuer, the Institution, the Underwriters or the Trustee has agreed to, nor is there any duty or obligation to, update this Official Statement to reflect any change or correction in the CUSIP® numbers printed above. No dealer, broker, salesperson, or other person has been authorized by the Issuer, the Institution or the Underwriters to give any information or to make any representations with respect to the Bonds, other than those contained in this Official Statement, and, if given or made, such other information or representations must not be relied upon as having been authorized by any of the foregoing. This Official Statement does not constitute an offer by any person to sell or the solicitation by any person of an offer to buy, nor shall there be any sale of the Bonds by any person in any jurisdiction in which it is unlawful for such person to make such offer, solicitation or sale. Certain information contained herein has been obtained from the Institution, The Depository Trust Company and other sources which are believed to be reliable, but has not been independently verified by, is not guaranteed as to accuracy or completeness, and is not to be construed as a representation of the Issuer or the Underwriters. The information and expressions of opinion herein are subject to change without notice and neither the delivery of this Official Statement nor any sale made hereunder shall, under any circumstances, create any implication that there has been no change in the affairs of the parties referred to above since the date hereof. References in this Official Statement to any legislation or documents, including the Act and the Agreement, do not purport to be complete. Refer to such legislation and documents for full and complete details of their provisions. Following issuance of the Bonds, a copy of the Agreement is expected to be on file with the Trustee. The Underwriters have provided the following sentence for inclusion in this Official Statement. The Underwriters have reviewed the information in this Official Statement in accordance with, and as part of, their responsibility to investors under the federal securities laws as applied to the facts and circumstances of this transaction, but the Underwriters do not guarantee the accuracy or completeness of such information. IN CONNECTION WITH THE OFFERING OF THE BONDS, THE UNDERWRITERS MAY OVER ALLOT OR EFFECT TRANSACTIONS THAT STABILIZE OR MAINTAIN THE MARKET PRICE OF THE BONDS AT LEVELS ABOVE THOSE WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN MARKET.
Load more

Recommended publications
  • Using Web-Based Annotation Tools for Bioinformatic Analyses of Proteomics Data
    Using web-based annotation tools for bioinformatic analyses of proteomics data Kasper Lage, PhD Massachusetts General Hospital Harvard Medical School the Broad Institute Overview of this session 1) Biological networks 2) Annotating genetic and proteomic data using biological networks 3) Tissue-specific networks with disease resolution 4) Emerging resources at the Broad Institute What is a biological network? Jeong et al., Nature 2001 1) Gene expression correlations 2) Protein-protein interactions 3) Co-mentioning in text D 4) Synthetic lethality 5) TF binding 6) Pathway database mining 7) Epigenetic data 8) All of the above Building a human protein-protein interaction network - InWeb Email [email protected] if you want to use the data. Lage, Karlberg et al., Nat. Biotech., 2007 Lage, Hansen et al. PNAS, 2008 Lage et al., Mol Syst Biol, 2010 Rossin et al., PLoS Genetics, 2011 Lage et al., PNAS, 2012 Social human networks D are a good model for understanding biological networks Social networks People are represented by “nodes”, work related interactions by “edges” daily weekly monthly Social networks People that work together are close to each other in the network daily weekly monthly Social networks People that work together are close to each other in the network daily weekly monthly Social networks People that work together are close to each other in the network daily weekly monthly Lone< wolf Social networks People that work together are close to each other in the network Do loci connect more than a random expectation? Quantify
    [Show full text]
  • Senior Counsel's Office
    Senior Counsel’s Office In its fifth year, fiscal year 2004, the Senior Counsel’s Office is MIT’s central in‐house counsel’s office, providing comprehensive legal services and counseling on MIT matters in all areas of concern to the academy and the administration (except intellectual property law). The office represents MIT’s president, provost, executive vice president, and chancellor, as well as the deans, vice presidents, the departments, laboratories, and research centers, and administrative offices. We also arrange for and manage outside legal services when needed and oversee all litigation. Our office includes MIT’s senior counsel Jamie Lewis Keith, contracts counsel Margaret Brill, and litigation and risk management counsel Mark DiVincenzo, as well as a law clerk, Kathryn Johnson. (In FY2004 our office also included a part‐time environmental counsel. In FY2005 the office will include an associate counsel.) We are problem solvers and strategic‐thinking partners for our clients. We strive to be enablers, helping MIT’s senior officers, faculty, and staff to accomplish their mission‐critical objectives and to make informed decisions. Our office also brings the lessons learned from litigation, other disputes, and major transactions back to the MIT community through counseling and education. These lessons support management and faculty initiatives to minimize and avoid those reputational, financial, operational, and legal risks that can be appropriately managed, while still achieving MIT’s core mission. The Senior Counsel’s Office advises
    [Show full text]
  • HBS Annual Report 2008
    2 0 0 8 h a r v a r d u n i v harvard university e r s i t y f i financial report n a n c i a l r e p o r t fiscal year 2008 001215 We want all students who might dream of a Harvard “ education to know that it is a realistic and affordable option . Education is fundamental to the future of individuals and the nation, and we are determined to do our part to restore its place as an engine of opportunity, rather than a source An upperclass student in Kirkland House sketches during her free time. of financial stress…This is a huge investment for Harvard, but there is no more important commitment we could make. Excellence and opportunity must go hand in hand. ” —President Drew Gilpin Faust announcing the Middle Income Financial Aid Initiative, December 10, 2007 2 message from the president 3 financial highlights s t 8 annual report of the harvard n e t management company n o 15 report of independent auditors c f financial statements o 16 e l b 20 notes to financial statements a t Message from the President I am pleased to present Harvard University’s financial report for fiscal 2008. Under very challenging market conditions, we achieved endowment returns of 8.6%, raising the endowment to $36.9 billion. Income from the endowment contributed approximately one-third of the University’s operating budget, while also supporting substantial capital outlays. In addition, our alumni and friends contributed $690.1 million during fiscal 2008, the second highest level of fundraising receipts in the University’s history.
    [Show full text]
  • CURRICULUM VITAE – June 13, 2017
    Chris Cotsapas PhD CURRICULUM VITAE – June 13, 2017 Education ARCS Imperial College, London UK (Biochemistry) 2000 BSc Imperial College, London UK (Biochemistry) 2000 PhD University of New South Wales, Sydney, Australia (Biochemistry & Molecular Genetics) 2007 Career/Academic Appointments: 2005-2007 Research Associate, Center for Human Genetics Research, MGH (Boston, MA) 2007-2010 Research Fellow, Center for Human Genetics Research, MGH (Boston, MA) 2005-present Research Affiliate, Broad Institute of MIT and Harvard (Cambridge, MA) 2010-present Visiting Faculty, Analytical/Translational Genetics Unit, MGH (Boston, MA) 2010-2016 Assistant Professor, Dept. of Neurology, Yale School of Medicine (New Haven, CT) 2011-2016 Assistant Professor, Dept. of Genetics, Yale School of Medicine (New Haven, CT) 2011-present Research Affiliate, Stanley Center for Psychiatric Research (Boston, MA) 2016-present Associate Professor, Dept. of Neurology, Yale School of Medicine (New Haven, CT) 2016-present Associate Professor, Dept. of Genetics, Yale School of Medicine (New Haven, CT) Funding Record Current Grants Agency: NIH/NIAID I.D.# R01 AI122220 Title: “Genomics of NFkB-mediated gene regulation in multiple sclerosis” P.I.: Chris Cotsapas PhD Percent effort: 12% Total costs for project period: $1,827,500 Project period: 09/01/2015 – 08/31/2020 Agency: European Commission (Horizon 2020 program) I.D.#: 733161 Title: “MultipleMS: Multiple manifestations of genetic and non-genetic factors in multiple sclerosis disentangled with a multi-omics approach to accelerate
    [Show full text]
  • 2012 Annual Report
    Memorial Sloan-Kettering Cancer Center 2012 ANNUAL REPORT A SHARED VISION A SINGULAR MISSION Nurse practitioner Naomi Cazeau, of the Adult Bone Marrow Transplant Service. PING CHI PHYSICIAN-SCIENTIST 10 STEPHEN SOLOMON ALEXANDER RUDENSKY INTERVENTIONAL IMMUNOLOGIST RADIOLOGIST 16 12 VIVIANE TABAR The clinicians and scientists of NEUROSURGEON Memorial Sloan-Kettering share a vision and 18 a singular mission — to conquer cancer. STEPHEN LONG STRUCTURAL BIOLOGIST They are experts united against a 20 SIMON POWELL complex disease. Each type of cancer R ADIATION ONCOLOGIST 24 ETHEL LAW is different, each tumor is unique. Set free NURSE PRACTITIONER in surroundings that invite the sharing of 26 ideas and resources, they attack the CHRISTINA LESLIE complexity of cancer from every angle COMPUTATIONAL BIOLOGIST and every discipline. 34 SCOTT ARMSTRONG PEDIATRIC ONCOLOGIST 30 TO JORGE REIS-FILHO EXPERIMENTAL PATHOLOGIST CONQUER 38 CANCER 04 Letter from the Chairman and the President A complete version of this report — 42 Statistical Profile which includes lists of our donors, 44 Financial Summary doctors, and scientists — 46 Boards of Overseers and Managers is available on our website at 49 The Campaign for Memorial Sloan-Kettering www.mskcc.org/annualreport. 4 5 Letter from the Chairman In 2012 the leadership of Memorial Sloan-Kettering endorsed Douglas A. Warner III These programmatic investments require leadership and and the President a $2.2 billion investment in a clinical expansion that will set vision. Our new Physician-in-Chief, José Baselga, joined the stage for a changing care paradigm into the next decade us on January 1, 2013. An internationally recognized and beyond.
    [Show full text]
  • The BBVA Foundation Frontiers of Knowledge Award in Biomedicine Goes to Tony Hunter, Joseph Schlessinger and Charles Sawyers
    The BBVA Foundation Frontiers of Knowledge Award in Biomedicine goes to Tony Hunter, Joseph Schlessinger and Charles Sawyers for opening the door to the personalized treatment of cancer The winners represent the three steps in research leading to this advance: Tony Hunter discovered tyrosine kinases, Joseph Schlessinger identified the principle through which they function, and Charles Sawyers brought this knowledge to the clinic and the development of novel cancer therapies Their contributions served initially to treat a variety of leukemia, transforming it from a fatal into a chronic disorder, but have since given rise to effective therapies for lung and breast cancer, melanoma and lymphomas, among other conditions José Baselga, Physician-in-Chief at the Memorial Sloan Kettering Cancer Center in New York and nominator of Charles Sawyers, described the contributions of the three laureates as marking “the birth of personalized anti-cancer medicine” Madrid, January 27, 2015.- The BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category is shared in this seventh edition by Tony Hunter, professor and Director of the Salk Institute Cancer Center in La Jolla, California; Joseph Schlessinger, Chairman of the Department of Pharmacology at Yale University School of Medicine, New Haven, and Charles Sawyers, Human Oncology and Pathogenesis Program Chair at the Memorial Sloan Kettering Cancer Center in New York, for “carving out the path that led to the development of a new class of successful cancer drugs.” For José Baselga, Physician-in-Chief
    [Show full text]
  • 100Th RAF Raffle – Kurt Durlesser and Evan Garcia OHRPP Updates
    Marcia L. Smith November 14, 2019 2 Welcome & Announcements 2009 - 2019 3 4 Agenda • Office of the Human Research Protection Program ◦ Roll-out of PI and Faculty Assurances – Moore Rhys • Extramural Fund Management ◦ Closing Expired Funds – Will Murdoch ◦ ERS Listserv Changes – Will Murdoch ◦ Ascend: Expenditure Type – Yoon Lee • UCLA Trivia and 100th RAF Raffle – Kurt Durlesser and Evan Garcia OHRPP Updates November 14, 2019 – 100th RAF 2 OHRPP Updates Annual PI and FS Assurances Human Research News Training opportunities 3 Annual PI and Faculty Sponsor Assurances In order to keep track of active studies that don’t require continuing review, OHRPP has worked with ORIS to create a mechanism for a yearly check-in with investigators. 4 Annual PI and Faculty Sponsor Assurances These will be required (in lieu of continuing review) to continue the following types of research: • Certified exempt • Studies determined eligible for expedited review • Research that has progressed to the point of only collecting results of clinical care procedures/tests for follow-up • Research that has progressed to the point of data analysis only • Studies where a UCLA IRB is relying on another IRB 5 Annual PI and Faculty Sponsor Assurances Automatic email notices (with instructions) will be sent out from the webIRB system: - 9 months after the initial approval (or last annual assurance) – 3 months before the assurance is due - 10 months after the initial approval (or last annual assurance) – 2 months before the assurance is due - 11 months after the initial approval (or last annual assurance – 1 month before the assurance is due - 12 months after the initial approval (or last annual assurance) – the day the assurance is due 6 Annual PI and Faculty Sponsor Assurances Important: If the PI (and faculty sponsor, if applicable) doesn’t complete the annual assurance, the study will be administratively closed PI proxies cannot complete the assurance 7 Annual PI and Faculty Sponsor Assurances If the PI has a faculty sponsor, the faculty advisor must complete their assurance first.
    [Show full text]
  • Lasker Awards Honor Trailblazers in Medical Research and Public Service
    EMBARGOED FOR RELEASE UNTIL SEPTEMBER 14, 2009 FROM: The Albert and Mary Lasker Foundation New York, New York CONTACT: Rubenstein Communications, Inc. Charles Zehren 212-843-8590 [email protected] Janet Wootten 212-843-8032 [email protected] 2009 LASKER AWARDS HONOR TRAILBLAZERS IN MEDICAL RESEARCH AND PUBLIC SERVICE: John Gurdon and Shinya Yamanaka, for Breakthrough Research in Nuclear Reprogramming and Stem Cells Brian J. Druker, Nicholas B. Lydon and Charles L. Sawyers, for Lifesaving Discoveries in Treatment of Leukemia Michael R. Bloomberg, for Landmark Policy and Philanthropic Initiatives to Reduce Tobacco Use and Foster Public Health New York, Sept. 13, 2009 - The Albert and Mary Lasker Foundation, which for 64 years has championed the greatest breakthroughs in medical research, today announced the winners of the 2009 Lasker Awards for outstanding accomplishments in basic medical and clinical medical research, and public service. The three awards—recognized as the most prestigious medical research awards in the United States today— honor six visionaries whose insight and courage has led to dramatic advances that will prevent disease and prolong life. John Gurdon of Cambridge University and Shinya Yamanaka of Kyoto University will receive the 2009 Albert Lasker Basic Medical Research Award for breakthrough discoveries into the process that instructs specialized adult cells to form stem cells. Brian J. Druker of Oregon Health & Science University, Nicholas B. Lydon, formerly of Novartis, and Charles L. Sawyers of Memorial Sloan-Kettering Cancer Center will receive the 2009 Lasker~DeBakey Clinical Medical Research Award for groundbreaking work on the treatment of chronic myeloid leukemia. New York City Mayor Michael R.
    [Show full text]
  • LLS AR 2005.Pdf
    LEUKEMIA LYMPHOMA MYELOMA 2005 Annual Report our mission Cure leukemia, Over its history, the Society has been the recognized leader in the fight against leukemia. Our name change to The Leukemia & Lymphoma lymphoma, Society in 2000 was simply perception catching up to reality. The Hodgkin’s Society’s objective is to find cures for all blood cancers, and to be disease and the leading resource for patients battling all of these cancers. myeloma, and This year, the Society took the first step in making access to specific improve the information and services simpler for patients with these cancers. quality of life We developed a color-coding system for the three main categories of blood cancers: Our new signature colors are green for leukemia, of patients and gold for lymphoma and blue for myeloma. Any information that their families. is relevant to all the diseases is coded burgundy. All print materials prepared for patients during this year reflect the new system, making access to important information and resources more efficient. You’ll also see our new colors in such e-newsletters as LeukemiaLinks, LymphomaLinks and MyelomaLinks. The next step will be to extend the new system to other venues, including access to information on the Society’s Web site. This year’s Annual Report displays the new colors with pride. They represent the ongoing efforts to constantly improve on the ways the Society serves and supports patients and those who love and 2 005 | care for them. AN N U AL R EPOR T leadership message We are fortunate to be able to report that fiscal year 2005 was a banner year for the Society in many ways.
    [Show full text]
  • Boston Tech Hub Faculty Working Group Annual Report: 2019-2020
    BOSTON TECH HUB FACULTY WORKING GROUP Annual Report 2019–2020 Technology and Public Purpose Project Belfer Center for Science and International Affairs Harvard Kennedy School 79 JFK Street Cambridge, MA 02138 www.belfercenter.org/TAPP Harvard John A. Paulson School of Engineering and Applied Sciences 29 Oxford St., Cambridge, MA 02138 www.seas.harvard.edu Statements and views expressed in this report are solely those of the authors and do not imply endorsement by Harvard University, Harvard Kennedy School, Harvard Paulson School, or the Belfer Center for Science and International Affairs. Design and Layout by Andrew Facini Copyright 2020, President and Fellows of Harvard College Printed in the United States of America BOSTON TECH HUB FACULTY WORKING GROUP Annual Report 2019-2020 Table of Contents Foreword ........................................................................................................................1 FWG Members and Guests .........................................................................................5 Introduction ................................................................................................................ 13 Summary ..................................................................................................................... 14 FWG Session Briefs: Fall 2019 ................................................................................19 FWG Session Briefs: Spring 2020 ..........................................................................31 Carol Rose, Executive Director
    [Show full text]
  • Angela N. Koehler
    Angela N. Koehler Broad Institute of MIT and Harvard Office: 617-714-7364 Chemical Biology Program Fax: 617-714-8943 7 Cambridge Center Email: [email protected] Cambridge, MA 02142 Website: www.broadinstitute.org/node/2445 Education Ph.D. Chemistry, Harvard University, 2003 B.A. Biochemistry and Molecular Biology, Reed College, 1997 Research Experience Investigator, Chemical Biology Program, Broad Institute 2009-present Project & Center Manager, Broad NCI Cancer Target Discovery and Development (CTD2) Center 2010-2012 Institute Fellow, Chemical Biology Program, Broad Institute 2003-2009 Director, Ligand Discovery, NCI Initiative for Chemical Genetics (ICG) at Harvard 2003-2009 Graduate Student, Department of Chemistry and Chemical Biology, Harvard University 1998-2003 Laboratory of Professor Stuart L. Schreiber Thesis: Small molecule microarrays: A high-throughput tool for discovering protein-small molecule interactions Researcher, Department of Chemistry, California Institute of Technology 1997-1998 Laboratory of Professor Barbara Imperiali Project: Biochemical reconstitution of the oligosaccharyltransferase (OST) complex Undergraduate Researcher, Department of Chemistry, Reed College 1995-1997 Laboratory of Professor Arthur Glasfeld Co-mentored by Professor Richard G. Brennan at Oregon Health Sciences University Thesis: Biochemical and structural characterization of the tRNA-modifying enzyme QueA from Escherichia coli Teaching Experience Research Advisor to postdoctoral fellows, undergraduates, high school students, and staff scientists 2003-present Broad Institute of MIT and Harvard Instructor, Biochemical Sciences Research (BS91r) 2004-2006, 2010-2011 Harvard University Associated Instructor, Experimental Research in the Life Sciences (LS100r) 2009 Harvard University Associated Instructor, Experimental Molecular and Cellular Biology (MCB100) 2004-2006 Harvard University Teaching Fellow, Chemical Biology (Chem 170) 1999, 2000 Harvard University, Professor David R.
    [Show full text]
  • BIOGRAPHICAL SKETCH NAME: Arlene H. Sharpe Era COMMONS
    OMB No. 0925-0001 and 0925-0002 (Rev. 12/2020 Approved Through 02/28/2023) BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FIVE PAGES. NAME: Arlene H. Sharpe eRA COMMONS USER NAME (credential, e.g., agency login): asharpe POSITION TITLE: George Fabyan Professor of Comparative Pathology EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.) DEGREE Completion (if Date FIELD OF STUDY INSTITUTION AND LOCATION applicable) MM/YYYY Radcliffe College, Cambridge, MA AB 05/1975 Biochemistry Harvard University, Cambridge, MA PhD 05/1981 Microbiology Harvard Medical School, Boston, MA MD 05/1982 Medicine A. Personal Statement My laboratory investigates T cell costimulation and its immunoregulatory functions. My laboratory focUses on the roles of T cell costimUlatory and coinhibitory pathways in regUlating immUne responses needed for the indUction and maintenance of T cell tolerance and effective antimicrobial and antitumor immunity. My laboratory has been at the forefront of this field for two decades. We have discovered T cell costimulatory pathways, and elucidated their functions, inclUding the functions of B7-1 and B7-2, CTLA-4, ICOS, PD-1 and PD-1 ligands. We are also involved in stUdies aimed at translating fUndamental Understanding of T cell costimUlation into new therapies for autoimmune diseases, viral infections, and cancer. Understanding how costimulatory pathways regulate tissUe inflammation, tolerance and anti-tumor immUnity is an important aspect of my cUrrent research.
    [Show full text]